Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Voluntis closes €20.75 million ($29 million) Series D financing round

Voluntis, a company pioneering therapeutic companion software, today announced the completion of its Series D financing round. With a total of €20.75 million ($29 million), this fund raising is one of the largest rounds of investment in the m-health sector this year.

28 Apr 2014

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.

26 Apr 2014

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

25 Apr 2014

Community-based structured weight loss program improves diabetes symptoms

Weight loss and control of blood sugar can reduce the risk of complications in patients with diabetes but this is difficult for many to achieve. A University of California, San Diego School of Medicine randomized controlled trial of obese adults with type 2 diabetes suggests that participants enrolled in a community-based structured weight loss program are able to shed more pounds, improve blood sugar control and reduce or eliminate insulin use and other medications compared to a control group.

25 Apr 2014

Increasing daily coffee consumption may lower type 2 diabetes risk

People who increased the amount of coffee they drank each day by more than one cup over a four-year period had a 11% lower risk for type 2 diabetes than those who made no changes to their coffee consumption, according to a new study led by Harvard School of Public Health (HSPH) researchers. In addition, the study found that those who decreased their coffee consumption by more than a cup per day increased their type 2 diabetes risk by 17%.

24 Apr 2014

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes.

23 Apr 2014

Catheter coating: an interview with Dr. Hinke Malda, Director of Medical Coatings, DSM Biomedical

DSM’s biomedical work brings new material innovation to market through the development of novel materials-based solutions that meet the present and future needs of the medical device and pharmaceutical industries.

22 Apr 2014

‘Profile America’ features world's most important medicine, insulin

One of world's most important medicines — insulin —became available for general use this month in 1923, saving the lives of millions of people suffering from diabetes. Insulin is a hormone produced by the pancreas and is critical in the processing of carbohydrates in the human body. I

22 Apr 2014

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Three Johns Hopkins University School of Medicine researchers have been awarded two-year grants for their work on potential treatments for diabetes, Novo Nordisk announced this month. Of the 110 initial submissions to the new Novo Nordisk Diabetes and Obesity Biologics Science Forum Program, only four projects were funded, three of which are led by Johns Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., Ph.D.

19 Apr 2014

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure.

17 Apr 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

It’s been over a decade since the first Diabetes Attitudes Wishes and Needs (DAWN) study showed that psychosocial aspects of diabetes pose specific challenges and barriers to optimal glycaemic control for people living with diabetes.

15 Apr 2014

Scientists solve a decades-long mystery of cell biology

A team led by scientists at The Scripps Research Institute has identified a long-sought protein that facilitates one of the most basic functions of cells: regulating their volume to keep from swelling excessively.

11 Apr 2014

Experts connect sleep deprivation to elevated risk of developing diabetes

Excessive noise is a common cause for a loss of sleep. Now, experts connect sleep deprivation to an elevated risk of developing diabetes.

10 Apr 2014

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.

10 Apr 2014

Gerresheimer’s revenues increase EUR 297.5M to 0.3% in first quarter 2014

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, began financial year 2014 with a solid start."I am satisfied with our performance in the first quarter of 2014.

10 Apr 2014

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone technology which enables accelerated absorption of prandial insulins. Humalog, which is now off-patent, has annual sales of USD 2.6 billion.

10 Apr 2014

Novel discovery could lead to new therapy to combat obesity, diabetes

By manipulating a biochemical process that underlies cells' energy-burning abilities, investigators at Beth Israel Deaconess Medical Center have made a novel discovery that could lead to a new therapy to combat obesity and diabetes.

10 Apr 2014

Insulin News and Research

Further Reading

Voluntis closes €20.75 million ($29 million) Series D financing round

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Community-based structured weight loss program improves diabetes symptoms

Increasing daily coffee consumption may lower type 2 diabetes risk

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Catheter coating: an interview with Dr. Hinke Malda, Director of Medical Coatings, DSM Biomedical

‘Profile America’ features world's most important medicine, insulin

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Protein expression predicts postop NSCLC recurrence, survival

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

Scientists solve a decades-long mystery of cell biology

Experts connect sleep deprivation to elevated risk of developing diabetes

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

Gerresheimer’s revenues increase EUR 297.5M to 0.3% in first quarter 2014

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Novel discovery could lead to new therapy to combat obesity, diabetes

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News